Nelson Advisors Big Questions in HealthTech Series: What is Clinical AI actually worth?

Nelson Advisors
5 hours ago
15 min read

The Valuation of Clinical Artificial Intelligence: Capital Allocation, Regulatory Assets and Valuation Methodologies in the Era of Health Tech 2.0

The global healthcare artificial intelligence market is undergoing a structural transition from speculative, early-stage point solutions to highly integrated, clinically validated enterprise platforms. In 2024 and 2025, the market expanded from $14.92 Billion to $21.66 Billion, with projections indicating a scale of $110.61 Billion by 2030, representing a compound annual growth rate of 38.6%. This rapid expansion is underpinned by a profound concentration of capital. Although transaction volumes have normalized, capital is clustering at the top end of the market. In 2025, global healthcare M&A values rose by 46% despite a 5% decline in transaction count, with approximately 70% of total transaction value concentrated in fewer than ten mega-deals.

For corporate boards, private equity sponsors, and strategic acquirers, the primary challenge is determining the intrinsic value of clinically validated AI assets when traditional software-as-a-service comparables fail to capture their underlying dynamics. Valuing these assets requires a multi-dimensional pricing framework that balances financial performance with structural defensibility, regulatory assets, clinical evidence, and deeply integrated workflow moats.

The Macroeconomic Re-Correction and the Rise of Health Tech 2.0

The speculative pricing cycle of the post-pandemic era, which valued platforms primarily on projected revenue, has been replaced by a rigorous valuation framework governed by the "Rule of 40 + Data". This transition marks the emergence of "Health Tech 2.0," a market regime characterized by disciplined capital allocation and the concentration of funding into market-dominant platforms.

In the European healthtech market, the total valuation is projected to scale from approximately $96.68 Billion in 2025 to over $222 Billion by 2030, representing a compound annual growth rate of 18.11%. However, this growth occurs against a backdrop of tight private capital markets. For example, the European market experienced a 44% decline in capital volume and a 46% drop in active deal count to 67 transactions in early 2026. Conversely, the average digital health venture deal size rose by 8% to $21.1 Million, proving that investors are concentrating capital in validated market leaders.

In the United States, a similar pattern of capital concentration has emerged. Total U.S. digital health funding reached $14.2 Billion in 2025 across 482 deals, representing a five-year low in deal count but a 42% rebound in average deal size to $29.3 Million. Clinical AI has captured the majority of this capital, securing 54% of all digital health funding in 2025. This concentration is driven by clear return-on-investment parameters, with healthcare AI tools yielding an average payback period of 14 months and returning $3.20 for every $1.00 invested.

To sustain operations between major funding rounds, clinical AI platforms are increasingly relying on bridge financing, with European bridge round frequency rising from 24% in 2024 to 37% in H1 2026.

Macroeconomic and Funding Metrics	2024 Actual	2025 Estimated	H1 2026 Projected
Average European Series A Round Size	$10.2M	$12.9M	$15.0M
European Digital Health VC Deal Size	$14.5M	$19.5M	$21.1M
European Healthcare Private Equity Value	$59.9B	$80.9B	$95.0B
US Venture Capital Funding (Total)	$10.5B	$14.2B	N/A
US Average Deal Size (Digital Health)	$20.7M	$29.3M	N/A
US Venture Capital Deal Count	509	482	N/A
Bridge Round Frequency (Europe)	24%	31%	37%
AI Share of Total Digital Health Funding	~45%	54%	N/A

Quantifying Clinical AI Value: Multi-Factor Valuation Adjustments

When determining what clinical AI is actually worth, acquirers must address a stark market bifurcation. The median healthcare AI startup valuation stands at approximately $525 Million, yet the top ten market leaders capture nearly 50% of the total ecosystem valuation, illustrating a highly concentrated market. There are currently 33 healthcare AI startups globally that have crossed the $1 Billion unicorn threshold.

Traditional comparable public company analysis is often ineffective because direct peers are rare, and standard software-as-a-service metrics fail to capture the value of proprietary data registries or clinical validation. Under a standard valuation model, a healthcare software company trades at 6.0x to 8.0x revenue. However, clinical AI platforms command premium multiples by leveraging multi-factor valuation adjustments that reflect their underlying data moats, clinical validation, and workflow integration.

For example, Tempus AI commands a valuation of $10 Billion to $14 Billion, trading at approximately 12.5x its projected full-year revenue. This multiple exceeds traditional SaaS benchmarks because it incorporates weighted contributions from proprietary data assets and multi-year pharmaceutical licensing contracts. Similarly, Abridge commands a $5.3 Billion valuation on approximately $100 million in actual ARR, trading at an implied multiple of ~50x. This premium multiple reflects the platform's native integration into Epic EHR systems and its potential to capture a significant share of the $250 Billion U.S. revenue cycle management market.

The valuation paradigm is further tested by massive capital-intensive infrastructure bets. Anthropic’s $965 billion valuation, secured alongside a historic $65 Billion Series H funding round, illustrates that the fight for clinical AI adoption is increasingly a physical capital war. Running HIPAA-compliant models like "Claude for Healthcare" at scale requires dedicated physical hardware rather than generic cloud space. This infrastructure requirement has driven co-investments from semiconductor giants like Samsung and Micron, shifting the investment thesis from simple software applications to the physical hardware of clinical decision-making.

Healthcare AI Sub-Sector	EV / Revenue Multiple	EV / EBITDA Multiple	Strategic Rationale and Key Value Drivers
AI-First Drug Discovery	8.0x – 15.0x	N/A (Pre-EBITDA)	Milestone-driven economics; upfront payments and $100M+ asset milestones; mitigates standard 10-year development timelines and $2B+ costs.
Genomics & Precision Medicine	6.0x – 12.0x	14.0x – 18.0x	Driven by data flywheels and scarcity of high-quality genomic cohorts; diagnostic variant interpretation accuracy.
Premium AI & Data Platforms	6.0x – 12.0x+	15.0x – 20.0x+	Grounded in proprietary, clinically validated algorithms; continuous Rule of 40 execution; deep EHR-native workflow integration.
Medical Imaging & Diagnostics	5.0x – 9.0x	14.0x – 20.0x	High workflow efficiency; PACS/RIS integration; FDA 510(k) or De Novo moats; established billing/reimbursement pathways.
Value-Based Care & Remote Monitoring	4.0x – 8.0x	12.0x – 15.0x	Direct CPT code billing; demonstrably reduces 30-day readmissions by over 15%; expands nurse staffing ratios.
General HealthTech SaaS	4.0x – 6.0x	10.0x – 13.0x	Stable retention profiles; standardized sales cycles; lacks proprietary data advantages or complex regulatory moats.
MedTech Hardware (MDR-Ready)	3.5x – 5.5x	11.0x – 14.0x	Regulated physical moats; high technical barriers to entry; burdened by hardware logistics and capital-intensive manufacturing.
Consumer Health & Wellness	2.0x – 4.0x	8.0x – 11.0x	Sensitive to discretionary spend; high consumer churn rates; lack of established clinical reimbursement pathways.
Unprofitable / Early-Stage AI	2.5x – 4.0x	N/A	Sub-scale point solutions; high burn rates; lacks deep enterprise workflow validation or clinical trial proof.

Public Health Tech 2.0 and Corporate Performance Benchmarks

The public markets have responded favorably to the financial discipline of Health Tech 2.0. Between 2024 and 2025, the digital health IPO window reopened with six companies going public, adding $36.6 Billion in fresh market capitalisation. These companies represent mature business models that combine consistent revenue growth with a clear path toward profitability.

The public Health Tech 2.0 cohort achieved an average enterprise value-to-revenue multiple of 7.2x, driven by strong annualised growth of 67% and stable free cash flow margins averaging -2%. Since its June 2024 listing, Tempus AI has risen 65%, adding $5.7 Billion to its market capitalisation. However, this public market momentum did not translate into active digital health IPOs in early 2026. While non-digital healthcare sectors thrived, such as biotechnology companies raising over $1 Billion in a single week and medical supply giant Medline completing a $6.26 Billion listing, the core digital health IPO window remained closed.

This closure has built up a massive backlog of highly valued private companies waiting in the wings. For example, Oura Health confidentially filed for an IPO in mid-2026. Transitioning from consumer wellness to clinical diagnostics, Oura sold over 5.5 Million smart rings by late 2025, with projected 2026 revenues of $1.5 Billion to $2.0 Billion supported by an $11 Billion Series E valuation.

Similarly, telemedicine platform Ro saw its revenue run rate accelerate to $598 Million, while employer-sponsored mental health leader Lyra Health reached an annualized run rate of $235 Million, covering 17 million lives.

Public Health Tech 2.0 Cohort	EV / Revenue Multiple	Annualized Revenue Growth Rate	Free Cash Flow Margin	Rule of 40 Score (Growth + FCF)
HeartFlow	13.8x	49%	-36%	13%
Tempus AI	9.3x	85%	-22%	63%
Caris Life Sciences	8.9x	117%	-7%	110%
Waystar	6.9x	12%	27%	39%
Hinge Health	5.7x	72%	26%	98%
Omada Health	2.5x	65%	-1%	64%
Health Tech 2.0 Average	7.2x	67%	-2%	65%

Historical Success Rates and Cumulative Probabilities

The probability weights applied to the cash flow projections are calibrated using empirical industry transition benchmarks. In the clinical software and medical device AI domains, the phase transition success rates and cumulative probabilities are structured as follows:

Development and Regulatory Milestone	Phase Transition Success Rate	Cumulative Probability from Pre-Clinical
Pre-Clinical Development	~60.0%	60.0%
First-in-Human / Phase I Trial	~65.0%	~39.0%
Pivotal Trial / Phase II Trial	~35.0%	~14.0%
FDA Submission / Phase III Trial	~60.0%	~9.6%
FDA 510(k) Clearance / Approval	85.0% – 95.0%	~8.0% – 9.0%

A 10 percentage-point upward shift in the Probability of Technical Success ($P(TS)$) at the pivotal trial stage can increase an asset's rNPV by 30% to 50%. This sensitivity highlights why acquirers must execute meticulous clinical and technical due diligence rather than relying on high-level market multiples.

Rare Disease and Genetic Validation Modelling

In biopharmaceutical and rare disease development, programs face extreme attrition, with only ~14% of early clinical candidates reaching commercialisation. According to systemic modelling frameworks developed by BridgeBio, under baseline rare disease assumptions, a program's neutral rNPV frontier of feasibility requires a treatable cohort of at least 2,772 patients at a 13% discount rate.

If a target company utilises genetics-based prevalence estimation to systematically identify and genetically validate previously undiagnosed patient cohorts, the underlying addressable market expands, lifting the asset's rNPV by approximately 4.5x (increasing the asset value from $307 Million to $1.37 Billion).

Furthermore, the financial hurdles are starkly illustrated by the gap between time-adjusted and risk-adjusted capital needs: while a program requires $2.5 Million in time-adjusted revenue to offset every $1 Million spent in preclinical R&D, it requires $17.9 Million in risk-adjusted revenue to offset the same expenditure when accounting for clinical attrition.

The Regulatory Moat and the Clinical Validation Evidence Hierarchy

In the clinical AI market, regulatory clearances and rigorous scientific validation serve as critical barriers to entry and direct value drivers. Acquirers use regulatory status to differentiate defensible clinical solutions from superficial diagnostic software.

The Clinical Validation Evidence Hierarchy

The depth of peer-reviewed clinical proof directly expands revenue multiples by de-risking commercial procurement and driving adoption across health systems:

Evidence Level	Valuation Multiple Uplift	Commercial and Strategic Impact
Randomized Controlled Trials (RCT)	+1.0x to 2.0x EV / Revenue	Considered the gold standard; demonstrates superior clinical outcomes versus standard of care; drives 2x faster hospital adoption and 30% higher average contract values.
FDA PMA (Class III Approval)	+2.0x to 4.0x EV / Revenue	Extremely high time and capital barrier; establishes near-monopolistic positioning for complex, high-risk diagnostic and therapeutic AI algorithms.
FDA De Novo Classification	+1.0x to 2.0x EV / Revenue	Applicable to novel technologies without existing predicates; creates a strong first-mover advantage and establishes the regulatory benchmark for future competitors.
FDA 510(k) Clearance	+0.5x to 1.5x EV / Revenue	De-risks commercial scaling; confirms substantial equivalence to existing predicates; standard threshold for diagnostic imaging and workflow tools.
Peer-Reviewed Publications	+0.5x to 1.0x EV / Revenue	Academic validation in high-impact journals (e.g., Nature Medicine, The Lancet Digital Health); builds clinical trust but lacks the binding legal protection of FDA clearances.

Regulatory Darwinism and Geographic Moats

Regulatory compliance acts as a binary valuation filter. For cross-border transactions, the implementation of complex frameworks like the European Union AI Act has created a divide. Clinical AI companies lacking transparent, explainable machine learning architectures face severe regulatory bottlenecks.

The friction of compliance can disrupt market access, as demonstrated by the clinical decision support platform OpenEvidence. Valued at $12 Billion in the United States and used by approximately 40% of US physicians, the company withdrew entirely from the United Kingdom and European Union markets, citing regulatory compliance uncertainties surrounding the EU AI Act.

Conversely, for established platforms, strict compliance regimes like the Medical Device Regulation (MDR) in Europe and data localization rules within the European Health Data Space (EHDS) function as geographical moats. Although these regulations slow down early model training by restricting access to un-permissioned data, they insulate approved, MDR-ready systems from external disruption, justifying a 20% to 30% valuation premium for compliant assets.

Clinical Validation and Evaluation Frameworks

Hospital governance boards and clinical AI steering committees increasingly utilize structured evaluation frameworks to mitigate patient safety risks and verify vendor claims. For example, Wolters Kluwer released a measured framework evaluating clinical AI at the point of care across three dimensions: clinical intent, knowledge integrity, and clinical impact. By moving beyond binary benchmarks, this methodology stress-tests models using clinical experts and adversarial "red teaming" to identify omissions or loss of context. Under this framework, UpToDate Expert AI achieved 99.9% clinical alignment across 15,000+ evaluated criteria.

Similarly, clinical evaluation studies published in early 2026 support case-specific, clinician-authored rubrics to measure the performance of EHR-embedded clinical documentation agents. In a study involving twenty clinicians who authored 1,646 rubrics across 823 patient encounters, clinician-authored rubrics successfully discriminated between high- and low-quality outputs, revealing a median score gap of 82.9%.

Furthermore, the integration of LLM-generated rubrics achieved ranking agreement ({\tau: 0.42 - 0.46}) that matched or exceeded clinician-to-clinician agreement ({\tau: 0.38 - 0.43}). Operating at roughly 1,000 times lower cost than manual physician reviews, automated LLM rubrics validated against clinician-authored baselines enable comprehensive, continuous monitoring of clinical model drift.

This expert-driven evaluation approach has been democratised through open-source initiatives like the Healthcare AI Model Evaluator. This platform allows healthcare organisations to bypass generic benchmarks and evaluate model outputs using local patient populations, clinical workflows, and real-time cost tracking.

Separating Moats from Wrappers: Systems of Action and Revenue Per FTE

The proliferation of "AI-enabled" healthcare software has forced corporate buyers to distinguish between low-defensibility "AI Wrappers" and high-defensibility "AI Moats".

Feature / Metric	High-Value "AI Moat" Platforms	Low-Defensibility "AI Wrappers"
Core Architecture	Proprietary models; closed-loop clinical feedback pipelines	Generic APIs; thin UI wrapper sitting on top of public models
Workflow Integration	EHR-native (Epic/Cerner); "zero-click" embedded interfaces	Standalone portals; requires separate physician login and manual copy-paste
Regulatory Defense	FDA cleared (510(k), De Novo, or PMA); MDR/IVDR certified	Bypasses regulatory pathways through low-risk CDS exemptions
Customer Stickiness	System of Action; >120% Net Revenue Retention (NRR)	Feature-level tool; high clinician churn and alert fatigue
Operational Capital Efficiency	$500,000 to $1,000,000+ Revenue per FTE	$200,000 to $400,000 Revenue per FTE (traditional SaaS)
Monetization Model	Shifting to value-based or outcome-driven pricing	Seat-based licensing; vulnerable to user count reductions

The Rise of Vertical AI Agents

The clinical AI market is transitioning away from horizontal copilots toward highly specialised, vertical AI agents designed to automate entire clinical and administrative workflows. This segment is scaling faster than any SaaS cohort in history, with Gartner forecasting that 40% of enterprise applications will embed task-specific AI agents by the end of 2026, up from less than 5% in 2025. In the legal and healthcare verticals, companies are reaching the $100 Million ARR milestone in record time. For example, legal agent platform Sierra crossed $100 Million ARR within seven quarters of launch, valuing the company at $15.8 Billion in May 2026, while its competitor Harvey reached a $300 Million ARR run rate.

In healthcare, enterprise vertical AI spend reached $1.5 Billion in 2025, led by Abridge and Hippocratic AI. Hippocratic AI, valued at $3.5 Billion on over $404 Million in raised capital, has deployed generative voice agents across fifty health systems, enabling automated post-discharge follow-ups and chronic care management. Similarly, ambient clinical documentation platforms like Abridge ($5.3B valuation), Nabla ($5.3B valuation on ~$316M raised), and Ambience Healthcare ($1.04B valuation on $243M raised) have evolved from basic transcription utilities into comprehensive systems of action.

Rather than billing purely on a per-seat model, these platforms are transitioning to outcome-based pricing, linking contract value to measurable reductions in administrative burden and accelerated billing cycles. By automating documentation and coding, tasks that historically consume 30% to 50% of a physician's working time, these platforms achieve gross margins of ~80% and scale enterprise revenues without a linear increase in headcount.

The Commercial Graveyard: Lessons from the PDTx Market Shakeout

The history of digital health contains critical warnings for corporate boards: clinical efficacy does not guarantee commercial sustainability. Acquirers must look beyond regulatory clearances and clinical trial data to evaluate a target's commercial strategy, workflow integration, and billing model.

The bankruptcies of prescription digital therapeutics (PDTx) pioneers like Pear Therapeutics and the operational restructuring of Akili Interactive illustrate the commercial limitations of relying solely on regulatory approvals.

Case Analysis: Pear Therapeutics

Pear Therapeutics developed prescription software applications that achieved strong scientific validation and secured formal FDA clearance. Its lead product, reSET, an app designed to improve abstinence and treatment retention in patients with substance use disorders, demonstrated strong performance in clinical trials. The software achieved a 40.3% abstinence rate in clinical testing, compared to just 17.6% for patients receiving standard care. On the back of this data and three FDA-cleared products, Pear completed a SPAC merger at a valuation of $1.6 Billion in late 2021.

Despite proving clinical utility and scaling its covered lives to over 31 Million, Pear's commercial business model collapsed. The company filed for Chapter 11 bankruptcy protection in 2023, and its assets were liquidated at auction for just over $6 Million, pennies on the dollar relative to its $400 Million in raised venture capital.

Case Analysis: Proteus Digital Health

A similar commercial failure occurred with Proteus Digital Health, which went bankrupt in 2020 after achieving a $1.5 Billion valuation. Proteus developed the first FDA-approved "smart pill," incorporating an ingestible sensor to monitor medication adherence. Despite establishing clinical proof of concept and securing regulatory clearances, the company failed to achieve commercial integration.

Both Pear and Proteus proved that securing an FDA clearance does not guarantee a sustainable commercial model. If a clinical tool requires separate clinician logins, lacks direct EHR integration, and relies on manual reimbursement approvals, the commercial friction remains too high to support enterprise scale.

Asset Liquidation Results

Following its Chapter 11 filing, Pear's clinical and intellectual property assets were split among four buyers for a total value of just over $6 Million, representing a complete write-down of its original $1.6 Billion valuation:

Acquired PDTx Asset	Purchasing Entity	Transaction Value	Strategic Intent and Target Pipeline
reSET and reSET-O	Harvest Bio LLC	$2.03M	Re-launching substance abuse PDTx under a new corporate structure (Harvest Bio).
Somryst (Insomnia PDTx)	Nox Health Group	$3.90M	Integrating digital insomnia therapy into Nox's sleep diagnostic network.
DTx Development Platform Patents	Click Therapeutics	$70,000	Absorbing underlying software IP into Click's competitive pipeline.
Migraine DTx Program	Welt Corp	$50,000	Expanding Welt's digital therapeutic portfolio in neurological conditions.

The Reimbursement Engine: CPT Coding and Payer Alignment

A clinical AI platform's commercial scalability depends heavily on its alignment with established billing and reimbursement pathways. Without integrated pathways to payment, adoption remains restricted to hospital operational budgets, capping contract values and multiple expansion.

Current Procedural Terminology (CPT) Classification

The American Medical Association's (AMA) CPT Editorial Panel classifies clinical AI technologies using Appendix S. This framework separates AI tools into three functional categories, which directly impact how insurers cover and pay for the services:

Assistive AI: Algorithms that analyze data (e.g., flagging a potential nodule on a chest X-ray) but require the clinician to perform the primary interpretation. These are coded as augmented services and are billable when paired with a physician's final report.
Augmentative AI: Systems where the AI performs a complex analysis or pattern recognition (e.g., digital pathology slide review or cardiac perfusion analysis), which the physician then reviews and integrates into their clinical decision-making. These services are highly billable and command favourable reimbursement rates.
Autonomous AI: Algorithms that perform the entire clinical task, including final interpretation and reporting, without active physician oversight at the point of care (e.g., autonomous retinal screening for diabetic retinopathy). These tools are fully billable, and their pricing models are structured around the direct replacement of professional fees.

Valuation Impact of 2026 CPT Code Updates

The explicit inclusion of AI-augmented medical codes in the CPT updates has established a clear link between clinical algorithms and practice revenue. This integration enables clinical AI platforms to process claims directly through standard Electronic Health Record (EHR) billing systems, reducing administrative friction.

For acquirers, the transition of an AI tool from a temporary Category III CPT code (designed for emerging technology and data collection) to a Category I CPT code (requiring extensive clinical efficacy data and widespread utilisation) represents a significant de-risking event. Securing Category I billing status typically triggers a 1.0x to 2.0x upward adjustment in a target's EV/Revenue multiple.

Conclusions and Strategic Imperatives for Corporate Boards

To navigate the transition into Health Tech 2.0, corporate boards, private equity sponsors, and strategic acquirers should adopt a structured set of valuation rules:

Reject Speculative Multiples in Favor of Multi-Factor Models: Boards must evaluate clinical AI targets using multi-factor frameworks that adjust traditional software metrics based on data moats, clinical validation, EHR integration, and billing pathways. Point-solution software applications that lack deep defensibility should be valued at standard SaaS ranges (4.0x to 6.0x revenue), while premium clinical platforms command multiples of 8.0x to 12.0x+.
Apply Correct rNPV Logic for Clinical-Stage Assets: When valuing pre-revenue or clinical-stage AI platforms, boards must utilize rNPV models that explicitly adjust projected cash flows based on historical phase transition probabilities. Acquirers must avoid the common valuation error of using high, venture-stage discount rates (15% to 30%) alongside probability weightings, as this double-counts risk and systematically undervalues clinical pipelines. The discount rate should be kept between 8% and 12% to accurately reflect the cost of capital.
Measure Hard Workflow Integration and the EHR Moat: Standalone software interfaces face rapid obsolescence and high user churn. Acquirers should apply a 20% to 30% valuation discount to any clinical tool that operates outside the physician's native EHR or PACS workflow. Premium valuations should be reserved for "systems of action" that are natively embedded inside environments like Epic or Oracle Cerner.
Validate the Billing and Payer Alignment Engine: As demonstrated by the PDTx market shakeout, diagnostic sensitivity and FDA clearances are commercially insufficient without integrated pathways to payment. Acquirers must evaluate a target's alignment with standardized billing codes, prioritize systems with established Category I CPT or NTAP reimbursement coverage, and verify that the clinical workflow supports compliant physician billing.
Target High Operational Leverage and ARR per FTE: Acquirers should scrutinize the target's internal capital efficiency. High-quality, scalable clinical AI platforms should demonstrate structural business model leverage, generating over $500,000 in recurring revenue per full-time employee. Targets requiring large clinical or consulting teams to support software deployment should be valued as lower-margin services businesses.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech